Journals / Glokom Katarakt / 2010 / Cilt: 5 - Sayı: 4

Posterior subcapsular cataract formation after intravitreal triamcinolone injection

İntravitreal triamsinolon enjeksiyonundan sonra arka subkapsüler katarakt gelişimi

Pages
203–206
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Additionally DM was found to be a risk factor for the development of PSC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the occurrence of posterior subcapsular cataract (PSC) after intravitreal triamcinolone acetonide (IVTA) injection and the factors associated with its development.
📊
Key Findings & Data:Materials and Methods: 173 eyes of 135 subjects in whom 4 mg IVTA was injected due to various etiologies were included.
💡
Conclusion & Impact:Additionally DM was found to be a risk factor for the development of PSC.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the occurrence of posterior subcapsular cataract (PSC) after intravitreal triamcinolone acetonide (IVTA) injection and the factors associated with its development. Materials and Methods: 173 eyes of 135 subjects in whom 4 mg IVTA was injected due to various etiologies were included. The association between PSC occurrence and age, intraocular pressure (IOP) increase, diabetes mellitus (DM) existence and the duration between PSC diagnosis and the IVTA injection was analyzed. Results: 74 female and 61 male were studied. The mean age was 61.7±10.32 (22-83) years old. The indications for IVTA injections were; diabetic macular edema in 115 eyes, the concomitant therapy with photodynamic therapy (PDT) for age related macular degeneration (AMD) in 33 eyes, macular edema due to retinal vein occlusions in 19 eyes (branch or central retinal vein occlusion), uveitic macular edema in 5 eyes and macular edema secondary to macroaneurysm. The follow-up period was 15.4±8.5 (4-36) months. The PSC formation was more frequent in diabetic subjects (28.6%) compared to nondiabetics (13.7%) (p<0.05). In patients followed-up for at least 12 months, PSC was more frequently developed (30.4% versus 11.4%; p<0.01). In 24.2% of the cases steroid-induced IOP elevation was treated with antiglaucoma medication. Age, sex and IOP increase was not associated with PSC formation. Conclusion: The occurrence of PSC increased after IVTA injection especially after 12 months follow-up period. Additionally DM was found to be a risk factor for the development of PSC.

Özet

Amaç: İntravitreal triamsinolon asetonid (İVTA) tedavisinden sonra arka subkapsüler katarakt gelişimi sıklığını ve bu tür katarakt gelişimine etkili olan faktörleri değerlendirmek amaçlandı. Gereç ve Yöntem: Çalışmaya çeşitli nedenelerle 4 mg intravitreal İVTA enjeksiyonu yapılan 135 hastanın 173 gözü alındı. Arka subkapsüler katarakt gelişimi ile cinsiyet, yaş, göz içi basıncının (GİB) yüksekliği, diyabetin varlığı ve enjeksiyondan sonra geçen süre arasındaki ilişki araştırıldı. Bulgular: Hastaların 74'ü kadın, 61'i erkekti. Yaş ortalaması 61.7±10.32 yıl (22-83) idi. İVTA enjeksiyonu endikasyonları; diyabetik makula ödemi (115 göz), yaşa bağlı makula dejenerasyonunun PDT ile kombine tedavisi (33 göz), retinal ven tıkanıklığına bağlı makula ödemi (santral ve dal, 19 göz), üveitik makula ödemi (5 göz) ve makroanevrizmaya bağlı makula ödemi (1 göz) idi. Takip süresi ortalama 15.4±8.5 ay (4-36 ay arası) idi. Arka subkapsüler katarakt gelişimi, diyabetik hastalarda (%28.6), diyabetik olmayanlara göre (%13.7) anlamlı derecede daha fazlaydı ( p<0.05). Takip süresi 12 ay ve üzerinde olanlardaki katarakt gelişimi (%30.4), 11 ay ve altı olanlardakine göre (%11.4) belirgin derecede fazlaydı (p<0.01). İVTA enjeksiyonundan sonra %24.2 oranında antiglokomatöz tedavi gerektiren GİB yüksekliği görüldü. Yaş, cinsiyet ve GİB artışının katarakt gelişimi ile ilişkisi saptanmadı. Sonuç: İVTA tedavisinden sonra özellikle 12 aydan sonra arka subkapsüler katarakt gelişim sıklığı artmaktadır. Ayrıca diyabet, arka subkapsüler katarakt gelişimi bakımından bir risk faktörü olarak görülmektedir.

🔖

Cite This Article

EROL, N., TOPBAŞ, S., ÖZER, A. (2010). Posterior subcapsular cataract formation after intravitreal triamcinolone injection. Glokom Katarakt, Cilt: 5 - Sayı: 4, 203–206. https://ajindex.com/articles/267689

References (16)

  1. Cunningham MA, Edelman JL, Shalesh Kaushal S.: Intravitreal steroids for Macular Edema: The Past, the Present, and the Future. Surv Ophthalmol. 2008
  2. Avcı R, Kaderli B, Akalp FD.: Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema. Clin Experiment Ophthalmol. 2006
  3. Özdek SC, Aydın B, Gürelik G, et al.: Effects of intravitreal triamcinolone injection on macular edema and visual prognosis in central retinal vein occlusion. Int Ophthalmol. 2005
  4. Karacorlu M, Mudun B, Ozdemir H et al.: Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behcet disease Am J Ophthalmol. 2004
  5. Chan A, Blumenkranz MS, Wu KH et al.: Photodynamic therapy with and without adjunctive intravitreal triamcinolone acetonide: a retrospective comparative study. Ophthalmic Surg Lasers Imaging. 2009
  6. Ş69. 6.Ruiz-Moreno JM, Montero JA, Amat P et al.: Secondary elevated IOP and cataracts after high-dose intravitreal triamcinolone and photodynamic therapy to treat choroidal neovascularization. J Glaucoma. 2009
  7. Özkiris As, Erkiliç K.: Complications of intravitreal injection of tri- amcinolone acetonide. Can J Ophthalmol. 2005
  8. Galor A, Margolis R, Brasil OM et al.: Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology. 2007
  9. Sampat KM, Garg SJ.: Complications of intravitreal injections. CurrOpin Ophthalmol. 2010
  10. Mukesh BN, Le A, Dimitrov PN et al.: Development of cataract and associated risk factors: the Visual Impairment Project. Arch Ophthalmol. 2006
  11. Leske MC, Chylack LT Jr, Wu SY.: The Lens Opacities Case-Control Study. Risk factors for cataract. Arch Ophthalmol. 1991
  12. Robman L, Taylor H.: External factors in the development of cataract. Eye. 2005
  13. Klein BE, Klein R, Lee KE et al.: Incidence of age-related cataract over a 15-year interval the Beaver Dam Eye Study. Ophthalmology. 2008
  14. Delcourt C, Cristol JR Tessier F et al.: Risk factors for cortical, nuclear, and posterior subcapsular cataracts: the POLA study. (Pathologies Oculaires Liees â I'Age.) Am J Epidemiol. 2000
  15. Thompson JT.: Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol. 2006
  16. Gillies MC, Kuzniarz M, Craig J et al.: Intravitreal triamcinolo-ne-induced elev